EVO
Evotec SE American Depositary Shares
Pharmaceutical Preparations
Best Pharmaceutical Stocks 2026 →
Evotec (EVO) Stock: Buy, Sell, or Hold?
$1.58
-0.08 (-4.82%)
âŧ
5d:
-6.51%
30d:
+11.27%
90d:
-19.39%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (45%)
Quality Score
36/100
Position
FAIR
30-Day Fair Range
$1.45 â $1.66
Position: FAIR
Forward P/E & Valuation
19.8x
CHEAP
vs 25.4x historical avg
Wall Street Target
$4.49
+184.1% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$1.50 / $1.82
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: EVO is fairly priced but lacks strong directional signals. At -8.1% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Get Alerted When EVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: EVO is currently trading at $1.58, which is considered fair relative to its 30-day fair value range of $1.45 to $1.66. From a valuation perspective, the stock is trading at a discount (Forward PE: 19.8) compared to its historical average (25.4). Remarkably, the market is currently pricing in an annual earnings decline of 8.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EVO is in a strong downtrend. Immediate support is located at $1.50, while resistance sits at $1.82. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: EVO scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.49 (+184.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EVO is in a strong downtrend. Immediate support is located at $1.50, while resistance sits at $1.82. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: EVO scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.49 (+184.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.45 -
$1.66
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
45.2%
Trading Range & Key Levels
30-Day Trading Range
$1.45 -
$1.66
Current vs Trading Range
FAIR
Support Level
$1.50
Resistance Level
$1.82
Current Trend
Strong Downtrend
Technical data as of
Nov 13, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (34/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.8%)
- BULLISH: Trading 184.1% below Wall St target ($4.49)
- WARNING: Composite score 36/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
19.75
Wall Street Target
$4.49
(+184.1%)
Revenue Growth (YoY)
0.6%
Profit Margin
-25.2%
Valuation Discount vs History
-8.1% cheaper
PE vs Historical
19.8 vs 25.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.1%
(market-implied from PE analysis)
1-Year Target
$1.45
(-8%)
2-Year Target
$1.33
(-16%)
3-Year Target
$1.23
(-22%)
3-Yr Target (if PE normalizes)
(PE: 20â25)
$1.58
(0%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 19.8 to 25.4
Stabilization Target:
$2.03
(+28.6%)
PE Expansion Potential:
+28.6%
Share EVO Analysis
Share this live EVO analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (EVO)
Bullish
1 Retail Mentions
Reddit / WSB Comments
1
Bullish
Last Tracked
Oct 31, 2026
Daily AI digest
AI Retail Discussion Summary:
Reddit & WallStreetBets discussions on EVO are bullish (sentiment score +0.49) across 1 tracked comments.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 14, 2026 6:09 AM ET
Data refreshes hourly during market hours. Next update: 7:09 AM
Data refreshes hourly during market hours. Next update: 7:09 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
29 analysts |
$208 | 30 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 39 SELL |
|
TEVA
Teva Pharma Industries LâĻ |
STRONG BUY
15 analysts |
$49 | 47 HOLD |
|
AMLX
Amylyx Pharmaceuticals IâĻ |
STRONG BUY
12 analysts |
$43 | 55 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 59 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive EVO Research Pages
